MedTrace Logo

Pregabalin for the Treatment and Prevention of Spinal Cord Injury Neuropathic Pain

NCT01479556 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2011-11-24

No results posted yet for this study

Summary

This study is a phase IV clinical trial with the objective of evaluating whether pain relief associated with pregabalin for at-level non-evoked and evoked neuropathic pain is more efficient during the early rather than late subacute phase of spinal cord injury.

Conditions

  • Neuropathic Pain
  • Spinal Cord Injuries

Interventions

DRUG

Pregabalin

Pregabalin Alpha2-delta calcium channel blocker. 150mg BID p.o.

DRUG

Placebo

150mg BID p.o.

Sponsors & Collaborators

  • Julian Taylor Green

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2014-05-31
Completion
2014-10-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01479556 on ClinicalTrials.gov